Table 2. Cell cycle distribution in HepG2, Bet-7402 and smmc-7721 cells among the six groups.

Cell cycle	Blank group	miR-126 mimics group	miR-126 inhibitors group	miR-126 inhibitors + si-EGFL7 group	Mimics control group	Inhibitors control group
HepG2
G0/G1 phase	56.81 ± 0.23	56.79 ± 0.73	57.06 ± 0.92	56.45 ± 0.51	57.17 ± 0.33	56.98 ± 0.56
G2/M phase	12.73 ± 0.31	12.52 ± 0.42	12.96 ± 0.27	13.08 ± 0.36	12.87 ± 0.39	12.99 ± 0.44
S phase	30.46 ± 0.25	30.69 ± 0.77	29.98 ± 0.71	30.47 ± 0.78	29.96 ± 0.22	30.03 ± 0.99
Bet-7402
G0/G1 phase	65.59 ± 1.02	64.62 ± 0.58	64.15 ± 0.62	64.30 ± 0.87	65.04 ± 1.05	64.27 ± 0.83
G2/M phase	13.38 ± 0.29	14.27 ± 0.31	13.79 ± 0.45	13.63 ± 0.38	14.16 ± 0.32	13.99 ± 0.12
S phase	21.03 ± 0.82	21.11 ± 0.80	22.06 ± 0.19	22.07 ± 0.96	20.80 ± 0.73	21.74 ± 0.71
smmc-7721
G0/G1 phase	73.17 ± 0.62	73.85 ± 0.76	73.21 ± 0.59	74.19 ± 0.93	73.73 ± 0.61	73.68 ± 0.72
G2/M phase	7.57 ± 0.33	7.83 ± 0.41	7.67 ± 0.28	7.84 ± 0.25	8.07 ± 0.36	7.90 ± 0.19
S phase	19.26 ± 0.57	18.32 ± 0.36	19.12 ± 0.33	17.97 ± 1.15	18.20 ± 0.89	18.42 ± 0.76

Note: miR-126, microRNA-126; EGFL7, epidermal growth factor-like domain 7; si-EGFL7; siRNA EGFL7.